Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2043 • 2019 ACR/ARP Annual Meeting
Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation
Natalie Sippl¹, Francesca Faustini ¹, Karine Chemin ¹, Iva Gunnarsson ² and Vivianne Malmström ³, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden
Background/Purpose: Arthritis is a common clinical feature of systemic lupus erythematosus (SLE), that can be present either at the onset or in later disease course.…
Abstract Number: 2523 • 2019 ACR/ARP Annual Meeting
Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
April Jorge¹, Na Lu ² and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA
Background/Purpose: SLE is a complex illness that can be associated with chronic pain. In recent years, an international opioid epidemic has become a major public…
Abstract Number: 2559 • 2019 ACR/ARP Annual Meeting
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
W. Winn Chatham ¹, Richard Furie ², Amit Saxena ³, Philip Brohawn ⁴, Erik Schwetje⁵, Gabriel Abreu ⁶ and Raj Tummala ⁵, ¹University of Alabama Medical Center, Birmingham, AL, ²Zucker School of Medicine at Hofstra/Northwell, New York, NY, ³NYU Langone Orthopedic Center, New York, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab is a fully human, IgG1κ monoclonal antibody that binds to the type I IFN receptor and inhibits activity of all type I IFNs.1…
Abstract Number: 2792 • 2019 ACR/ARP Annual Meeting
The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis
Valentin Ritschl¹, Ricardo Ferreira ², Rúben Fernandes ², Eduardo Santos ², Essi Juutila ³, Erika Mosor ¹, Kim Fligelstone ⁴, Helena Gaspar ⁵, Linda Schraven ⁶, Judy Ammerlaan ⁷, Georg Stummvoll ⁸, Maria João Salvador ², Janet Poole ⁹, Cornelia van den Ende ¹⁰, Carina Boström ¹¹ and Tanja Stamm ¹, ¹Medical University of Vienna, Vienna, Austria, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Metropolia University of Applied Sciences, Helsinki, Finland, ⁴Federation of European Scleroderma Associations, Tournai, Belgium, ⁵Portuguese League Against Rheumatic Diseases, Portugal, Portugal, ⁶Federation of European Scleroderma Associations, Sweden, Sweden, ⁷University Medical Centre, Utrecht, Netherlands, ⁸Klinikum Malcherhof Baden, Baden, Austria, ⁹University of New Mexico, Albuquerque, NM, ¹⁰Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ¹¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoimmune Connective Tissue Disorders (CTDs), including Mixed Connective Tissue Disorders (MCTD), systemic sclerosis (SSc) and systemic lupus erythematous (SLE) can lead to Raynaud phenomenon,…
Abstract Number: 75 • 2019 ACR/ARP Annual Meeting
Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Hadijat Makinde¹, Elise Mike ², Chaim Putterman ³, Deborah Winter ⁴ and Carla Cuda ⁵, ¹Northwestern University, Chicago, IL, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, ⁵Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. More than 50% of patients experience neuropsychiatric symptoms of…
Abstract Number: 642 • 2019 ACR/ARP Annual Meeting
Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus
Elisabet Svenungsson ¹, Johanna Gustavsson ², Giorgia Grosso ², Iva Gunnarsson ², Bo Nilsson ³, Anders Larsson ³, Anders Bengtsson ⁴ and Christian Lood⁵, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Uppsala University, Uppsala, Sweden, ⁴Lund University, Lund, Sweden, ⁵University of Washington, Seattle
Background/Purpose: Complement components, including C4d, can be detected on the surface of activated platelets and they have been associated with vascular disease in systemic lupus…
Abstract Number: 703 • 2019 ACR/ARP Annual Meeting
Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics
Nimisha Schneider¹ and Andrew Thompson ¹, ¹PatientsLikeMe, Cambridge
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic auto-immune condition characterized by systemic inflammation that can exacerbate (flare) unpredictably, causing widespread organ damage. Identification of…
Abstract Number: 1021 • 2019 ACR/ARP Annual Meeting
Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice
Michelle Huang¹, Ariel Stock ², Elise Mike ², Roland Kolbeck ³ and Chaim Putterman ⁴, ¹Albert Einstein College of Medicine, Bronx, ²Albert Einstein College of Medicine, Bronx, NY, ³MedImmune, Gaithersburg, MD, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: Many systemic lupus erythematosus patients display a type I interferon (IFN) signature, and IFNα levels and gene signatures have been positively correlated with disease…
Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
JB Boone¹, S. Bobo Tanner ¹ and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…
Abstract Number: 1581 • 2019 ACR/ARP Annual Meeting
Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Renata Hansen¹, Julia Simard ², Mikkel Faurschou ³, Søren Jacobsen ⁴ and Titilola Falasinnu ⁵, ¹Copenhagen Lupus and Vasculitis Clinic, Denmark, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA, ³Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Hovedstaden, Denmark, ⁴Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Denmark, ⁵Department of Health Research and Policy, Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Risk of end stage renal disease (ESRD) is increased in patients with systemic lupus erythematosus (SLE). Due to lifestyle –related risk factors, inflammation, and…
Abstract Number: 1622 • 2019 ACR/ARP Annual Meeting
Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review
Sofia Alfred¹, Lina Khoja ¹, Melanie Anderson ², Zahi Touma ³ and Lisa Engel ⁴, ¹University of Toronto, Toronto, Canada, ²University Health Network, Toronto, Canada, ³University Health Network, University of Toronto, Toronto, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Approximately 33 to 43% of individuals with SLE experience cognitive impairments…
Abstract Number: 1865 • 2019 ACR/ARP Annual Meeting
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Fatima Barbar-Smiley¹, Stephanie Lemle ¹, Cagri Yildirim-Toruner ¹, Edward Oberle ¹, Darby McDonald ¹, Vidya Sivaraman ² and Stacy Ardoin ¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) affects both adults and children with an estimated prevalence in children of 8/100,000. More than 1000 deaths related to SLE…
Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Jaime Coral-Enriquez ¹, Mauricio Restrepo ², Gloria Vasquez ³, Carlos H Muñoz-Vahos ⁴, Daniel Jaramillo ⁵, Adriana Vanegas-García ⁴, Ruth Eraso ⁶, Johanna Hernández ⁷, Fabian Jaimes ⁸ and Luis Gonzalez², ¹Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, ²Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, ³University of Antioquia, Medellin, Antioquia, Colombia, ⁴Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁵Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, ⁶Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, ⁷Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, ⁸Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia
Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…
Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Christopher Collins ¹, Gail Kerr ², Joan Von Feldt ³, Bernie Rubin ⁴, Arie Katz ³, Vanessa Castellano ⁵, Jake Chung ⁴ and Christopher Bell⁵, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²Washington DC VA Medical Center, Georgetown and Howard Universities, Washington DC, DC, ³GSK, Philadelphia, PA, ⁴GSK, Phildelphia, PA, ⁵GSK, Research Triangle Park, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…
Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Jun Kikuchi¹, Hironari Hanaoka ¹, Shuntaro Saito ¹, Tatsuhiro Oshige ¹, Kazuoto Hiramoto ¹, Yuko Kaneko ¹, Noriyasu Seki ², Hideto Tsujimoto ² and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].